“arqule” Archives

in
Entry Author Date Location
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule 12/09/19 New York
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
ArQule’s Lead Cancer Drug Fails Another Clinical Trial 01/11/13 Boston
Myriant Gets $60M, BioVex Bought By Amgen, Raindance Wraps Up $37.5M, & More Boston-Area Deals News 01/26/11 Boston
ArQule Raising $41M in Stock Sale 01/21/11 Boston
Lycera Keeps Its Investors Happy, Snags $11M to Pursue New Autoimmune Drugs 04/28/10 Detroit Ann Arbor
The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten 10/08/09 Boston
Biotech Survival Index 2: Boston Life Sciences Companies Squirrel Away More Cash for Long Winter 03/17/09 Boston
Broad Institute Scientists’ Forma Therapeutics Raises $25M, Aims to Knock Out Underpinnings of Cancer 01/06/09 Boston
New RNAi Drugs, Major Cutbacks at Targanta, Big Partnerships for Arqule and Archemix, & More Boston-Area Life Sciences News 12/24/08 Boston
Outsourced Chemistry Shop, BioBlocks, Sees Growth in San Diego and Hungary 12/23/08 San Diego
ArQule Snags $60M From Daiichi Sankyo 12/19/08 Boston
Another Next-Generation RNAi Startup Emerges, Makes Big Claims About Its Ability to Silence Bad Genes 12/18/08 Boston
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter 11/25/08 Boston
A Lawsuit for Biogen, A Suitor for Millennium, The Suits Who Made Their Own Fate, & More Life Sciences News 04/16/08 Boston
ArQule Gets a New CEO 04/15/08 Boston
ArQule CEO Hill to Leave Post, Remains Mum on Next Step as Firm Hunts for Replacement 01/08/08 Boston
Page 1 of 1